Financial and Business Highlights
This interim report provides a comprehensive overview of MicroTech Medical's performance for the six months ended June 30, 2022. The company recorded significant revenue growth, driven by the commercialization of its innovative diabetes management products such as AiDEX G7 CGMS and Equil patch insulin pumps. The report details advancements in product development, including the expansion of Equil's application to children and adolescents, and progress in the development of the AiDEX X CGMS and PanCares artificial pancreas system.
MicroTech Medical is committed to enhancing diabetes treatment and monitoring solutions globally. The company is focused on expanding its market presence, strengthening its R&D capabilities, and establishing a robust cloud-based diabetes management platform to better serve patients worldwide.
Key Products and Pipeline
The report highlights MicroTech Medical's diverse product portfolio, which includes:
- Equil Patch Insulin Pump System: A semi-disposable patch insulin pump offering advantages in discretion, precision, and user-friendliness.
- AiDEX G7 CGMS: A calibration-free, real-time continuous glucose monitoring system designed to improve diabetes management and reduce risks associated with hyperglycemia and hypoglycemia.
- AiDEX X CGMS: A next-generation CGMS focusing on ease of use and cost-effectiveness.
- PanCares Artificial Pancreas System: A closed-loop system integrating insulin delivery, CGMS, and control algorithms for automated diabetes management.
- BGMS Products: Including the Exactive Pro, a three-in-one testing system for blood glucose, ketone, and uric acid.
The company continues to invest in research and development, aiming to bring advanced medical devices to market and improve the lives of diabetic patients.
Corporate Information
MicroTech Medical (Hangzhou) Co., Ltd. is a joint stock company incorporated in the People's Republic of China. Key corporate information, including the board of directors, management, and registered office details, are provided within the full report.
For more detailed financial information and business strategies, please refer to the complete 2022 Interim Report available on the MicroTech Medical website: www.microtechmd.com.
